Screening for Prostate Cancer with Prostate-specific Antigen: The Journey Continues

被引:3
|
作者
Avagimyan, Ashot [1 ]
Gvianishvili, Tamuna [2 ]
Gogiashvili, Liana [3 ]
Kakturskiy, Lev [4 ]
Sarrafzadegan, Nizal [5 ]
Aznauryan, Artashes [6 ]
机构
[1] Yerevan State Med Univ, Anat Pathol Dept, Yerevan, Armenia
[2] Ivane Javakhishvili Tbilisi State Univ, Alexandre Natishvili Inst Morphol, Dept Clin & Expt Pathol, Tbilisi, Georgia
[3] Ivane Javakhishvili Tbilisi State Univ, Alexandre Natishvili Inst Morphol, Dept Clin & Expt Pathol, Tbilisi, Georgia
[4] Russian Soc Pathol, FSBI Res Inst Human Morphol, Moscow, Russia
[5] Isfahan Univ Med Sci, Isfahan Cardiovasc Res Inst, Esfahan, Iran
[6] Yerevan State Med Univ, Histol Dept, Yerevan, Armenia
关键词
TRASTUZUMAB-INDUCED CARDIOTOXICITY; SUBCLINICAL HYPOTHYROIDISM; RISK-FACTOR; ANTHRACYCLINE; DOXORUBICIN; DISEASE; PACLITAXEL; PREDICTION; STRESS; HEART;
D O I
10.1016/j.cpcardiol.2021.101051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in the population, as well as the economic burden of the health care system. Currently, CVDs account for more than 17.6 million deaths a year and are projected to exceed 23.6 million by 2030. Unstable atheroma, and its rupture, underlies the pathology of most cardiovascular complications, particularly acute coronary syndrome, mortality from which, compared with other CV events, remains the leading one. Despite numerous efforts by WHO, national health systems, and medical authorities, the incidence and mortality from cardiovascular events remain critically high. Thus, the search for new risk factors for the development of CV pathology looks very relevant. Our working group decided to amalgamate our research data, which reflects the study of modern risk factors from the Armenian, Russian,
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Usefulness of prostate-specific antigen velocity in screening for prostate cancer
    Ito, K
    Yamamoto, T
    Ohi, M
    Kubota, Y
    Fukabori, Y
    Kurokawa, K
    Suzuki, K
    Yamanaka, H
    INTERNATIONAL JOURNAL OF UROLOGY, 2002, 9 (06) : 316 - 321
  • [22] Recommendations on screening for prostate cancer with the prostate-specific antigen test
    Bell, Neil
    Gorber, Sarah Connor
    Shane, Amanda
    Joffres, Michel
    Singh, Harminder
    Dickinson, James
    Shaw, Elizabeth
    Dunfield, Lesley
    Tonelli, Marcello
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2014, 186 (16) : 1225 - 1234
  • [23] Free serum prostate-specific antigen and screening for prostate cancer
    Bangma, CH
    Kranse, R
    Schroder, FH
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (11): : 837 - 838
  • [24] Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
    Cabarkapa, Sonja
    Perera, Marlon
    McGrath, Shannon
    Lawrentschuk, Nathan
    PROSTATE INTERNATIONAL, 2016, 4 (04) : 125 - 129
  • [25] Prostate-Specific Antigen Screening and Mortality from Prostate Cancer
    Stephen W. Marcella
    George G. Rhoads
    Jeffrey L. Carson
    Frances Merlino
    Homer Wilcox
    Journal of General Internal Medicine, 2008, 23 : 248 - 253
  • [26] SCREENING FOR PROSTATE-CANCER BASED ON PROSTATE-SPECIFIC ANTIGEN
    ANDRIOLE, GL
    EUROPEAN UROLOGY, 1995, 27 : 6 - 8
  • [27] Rural residence and prostate cancer screening with prostate-specific antigen
    Stamatiou, K.
    Skolarikos, A.
    RURAL AND REMOTE HEALTH, 2009, 9 (02):
  • [28] PROSTATE-SPECIFIC ANTIGEN DENSITY AND AGE-SPECIFIC PROSTATE-SPECIFIC ANTIGEN VALUES - THE SOLUTION OF PROSTATE-CANCER SCREENING
    PAUL, R
    BREUL, J
    HARTUNG, R
    EUROPEAN UROLOGY, 1995, 27 (04) : 286 - 291
  • [29] Age-adjusted prostate-specific antigen and prostate-specific antigen velocity cut points in prostate cancer screening
    Goebell, Peter J.
    Wullich, Bernd
    STRAHLENTHERAPIE UND ONKOLOGIE, 2008, 184 (05) : 283 - 284
  • [30] Prostate-specific antigen screening
    Biehn, John
    CANADIAN FAMILY PHYSICIAN, 2011, 57 (09) : 993 - 993